Table 1.
Demographic and clinical data.
| (a) | |||
|---|---|---|---|
| PD (N = 15) | HCs (N = 14) | ||
| Mean ± SD | Mean ± SD | p (<0.05) | |
| Sex | 10 M, 5 F | 9 M, 5 F | n.s. (0.89) |
| Age | 69.93 ± 8.75 | 69.57 ± 6.06 | n.s. (0.90) |
| Education | 11.60 ± 4 | 13. 07 ± 2.58 | n.s (0.25) |
| MMSE | 29.13 ± 0.64 | 29.07 ± 1 | n.s. (0.84) |
| MMPSE | 29.79 ± 2.29 | — | |
| LEDD | 632.83 ± 186.55 | — | |
| (b) | |||
|---|---|---|---|
| PD on (N = 15) | PD off (N = 15) | ||
| Mean ± SD | Mean ± SD | p (<0.05) | |
| UPDRS-III | 17.67 ± 6.80 | 37.21 ± 10.04 | s. (0.0001) |
| H&Y | 2.08 ± 0.18 | 2.32 ± 0.32 | s. (0.02) |
(a) Summary of demographics and clinical scores for the PD and HCs groups. age: age in years, education: education in years, MMSE mini-mental state examination, MMPSE mini-mental Parkinson state examination, LEDD levodopa equivalent daily dose.
(b) Summary of motor scale scores (unified PD rating scale, section III [UPDRS-III]) and disease progression (Hoehn and Yahr [H&Y] scale) of PD patients tested on- (with dopaminergic medication) and off-condition (without dopaminergic medication). n.s. non-significant, s significant.